Meeting
2022 ASCO Genitourinary Cancers Symposium
Impact of AR-V7 and other androgen receptor splice variant expression on outcomes of post-prostatectomy salvage therapy.
Authors
Keisuke Otani
Massachusetts General Hospital, Harvard Medical School, Boston, MA
Keisuke Otani , David Joseph Konieczkowski , Michael Drumm , Yukako Otani , Shulin Wu , Elai Davicioni , Philip James Saylor , Chin-Lee Wu , Jason A. Efstathiou , David Tomoaki Miyamoto
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 274)
DOI
10.1200/JCO.2022.40.6_suppl.274
Abstract #
274
Poster Bd #
M5
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2021 Genitourinary Cancers Symposium
Interim analysis of STARTAR: A phase II salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
First Author: Edwin Melencio Posadas
Poster
2024 ASCO Genitourinary Cancers Symposium
EORTC GUCG 2238 De-escalate: A pragmatic trial to revisit intermittent androgen-deprivation therapy in metastatic hormone-naïve prostate cancer in the era of new AR pathway inhibitors.
First Author: Guillaume Grisay